Children's Hospital of Orange County
Orange, California, 92868, United States
NCT Number: NCT04098211
The purpose of this study is to gather information on the possible symptoms that patients with atypical neuronal ceroid lipofuscinosis type 2 (also known as aTPP1 or atypical tripeptidyl peptidase deficiency) have and how they change over time.
This study is active but is not currently recruiting participants.
Notify Me4 year and older
All sexes
Observational
Orange, California, 92868, United States
This study aims characterize the natural history of atypical TPP1 deficiency patients via longitudinal multidisciplinary assessments.
Multifaceted clinical, laboratory, imaging, and diagnostic assessments will be performed at regular intervals upon enrolled aTPP1 deficiency patients, collated, and analyzed over a three-year longitudinal period.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At baseline and every 3 months afterwards, up to 3 years
Modified Hamburg Rating Scale. The rating scale consists of two domains (motor function, language). Within each domain, a score from 0 to 3 is assigned and overall scores are calculated by summing the domain scores for final rating of 0 (severely impaired) to 6 (normal).
Time frame: At baseline and every 6 months afterwards, up to 3 years
Standard ERG will be performed to measure function of cones and rods of the inner and outer photoreceptor layers which amplitudes are typically decreased in classical TPP1 deficiency.
Time frame: At baseline and every 6 months afterwards, up to 3 years
OCT is non-invasive, quantitative measurement of inner and outer photoreceptor layer thicknesses.
Time frame: At baseline and every 6 months afterwards, up to 3 years
Gait assessment is acquired utilizing infrared sensors applied to participant's clothing and will include collection of walking speed, cadence, swing phase, stride length and time, walking base width, stance phase, and double limb support phase.
Time frame: At baseline and every 12 months afterwards, up to 3 years
Pre/post-contrast images will be acquired to perform volumetric studies and white matter assessment.
Time frame: At baseline and every 12 months afterwards, up to 3 years
EEG will be obtained and analyzed for changes that may be distinctive for TPP1 deficiency. Evaluation of background activity, mild/moderate/severe slowing for age.
Time frame: At baseline and every 12 months afterwards, up to 3 years
EEG will be obtained and analyzed for changes that may be distinctive for TPP1 deficiency. Interictal discharges: location, focal/generalized, discharge burden.
Time frame: At baseline and every 12 months afterwards, up to 3 years
Seizures.
Time frame: At baseline and every 12 months afterwards, up to 3 years
Photoparoxysmal response: present/absent
Time frame: At baseline and every 12 months afterwards, up to 3 years
WISC-IV will generate a full scale of intelligence quotient and five primary index scores: Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory, and Processing Speed. The WAIS-IV is scored by summing the raw scores for each subtest; each raw subtest score is then converted to a scaled scored. They are then combined to create a Full Scale IQ Index score. Test takers will also be given a score on the General Ability Index (GAI).
Time frame: At baseline and every 3 months afterwards, up to 3 years
Standard laboratory testing and biobanking / storage of remaining CSF (via Ommaya if on enzyme replacement; via lumbar puncture if not on enzyme replacement)
Children's Hospital of Orange County
Other
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency (Neuronal Ceroid Lipofuscinosis Type 2) Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03862274
Batten Disease, CLN2
Columbus, Ohio, United States
View Trial DetailsNCT04808297
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Pisa, PI, Italy
View Trial DetailsNCT01873924
Batten Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Rochester, New York, United States
View Trial DetailsNCT01793168
1p36 Deletion Syndrome, 3-Methylglutaconic Aciduria, Type V
Sioux Falls, South Dakota, United States
View Trial Details